The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression

Buchborn and colleagues frame the ego as a central but ambiguously defined construct in psychedelic research and psychotherapy. They note that while phenomena such as ego dissolution are widely discussed in the psychedelic literature, the original psychodynamic formulation of the ego has received little sustained attention. Contemporary measures in the field tend to focus on phenomenology (subjective experience) rather than on the ego's functional roles, and the psychodynamic perspective has been comparatively sidelined by other frameworks such as cognitive behavioural approaches and the broader ‘‘self’’ construct. This review aims to reintroduce and synthesise psychodynamic concepts of the ego for the psychedelic literature. The authors set out to (1) describe core ego functions from drive and ego psychology (including ego boundaries, defenses, synthesis and the mental representation of the self), (2) evaluate evidence that psychedelics transiently disrupt these functions—producing regression and loosening of defenses—and (3) explore therapeutic implications, especially from the psycholytic tradition in which repeated lower-dose sessions aim to reach and remodel character (habitual ego patterns). They propose that for psychedelic-assisted therapy to produce sustained change it must psycholytically access and integrate the characterological roots of maladaptive ego patterns within a robust therapeutic alliance.

This paper is a theoretical, narrative review that draws on psychodynamic writings (classical drive and ego psychology and later ego-psychological developments), historical clinical observations from first-wave psychedelic research, contemporary psychometric work in altered states research, and emerging neurobiological models of psychedelic action. The authors synthesise conceptual material (definitions and taxonomies of ego functions, character types and defenses), qualitative clinical reports, and selected empirical findings (e.g., neuroimaging studies linking psychedelics to network desynchronization), to develop an integrative psychodynamic model of psychedelic-ego interaction. The extracted text does not present a formal methods section detailing a systematic search strategy, databases searched, inclusion/exclusion criteria, or a risk-of-bias assessment. Instead, the approach appears to be selective and integrative: classic psychodynamic sources are combined with examples from psychedelic clinical observations and recent neuroscientific hypotheses (e.g., REBUS, DMN decoupling). Where historical clinical series are cited, sample descriptors are given in passing (for example, Savage's 300 clinical observations on 38 subjects and other authors' cumulative session counts), but there is no indication that the review followed a reproducible, quantitative meta-analytic protocol.

The review organises evidence and arguments around several interrelated themes. First, psychedelics reliably produce phenomena tied to ego disturbance: depersonalization, derealization, and ego dissolution. These are commonly captured in altered-states questionnaires (for example, the 5D-ASC scales for oceanic boundlessness and dread of ego dissolution) but most psychometric work emphasises phenomenology rather than functional ego capacity. Second, the authors report historical clinical observations indicating that psychedelics can induce regressions to earlier modes of psychic functioning. Clinical series reviewed include hundreds to more than a thousand observed sessions in the first-wave literature; observers described increases in affect arousal, an initial amplification of cathexis followed by decathexis (withdrawal of investment in self and environment), immature thinking, and loosening of defenses. Different character types appear differentially susceptible to regression—obsessive-type characters, for example, may require higher doses to overcome entrenched defensive rigidity. The psycholytic model emphasises repeated, lower-dose sessions (often 10–50) to facilitate progressive access to characterological material, whereas the ‘‘psychedelic’’ model emphasises one to a few high-dose sessions intended to trigger peak or conversion-like experiences. Third, neurobiological findings and hypotheses are integrated with psychodynamic constructs. The authors describe models in which the ego corresponds to large-scale network synchrony—especially the default mode network (DMN)—and psychedelics disrupt this synchrony (reduced alpha amplitude, DMN decoupling). Decoupling of medial temporal/hippocampal limbic structures from the DMN is proposed to disinhibit affective, ‘‘primary-process’’ dynamics. The REBUS model (relaxed priors under psychedelics) is used to link reduced top-down predictive control with greater bottom-up access of limbic—and potentially archaic—content, producing perceptual and affective ‘‘discharges’’ (including pseudo-hallucinations) that can carry symbolic or therapeutic significance. Fourth, the review summarises psychodynamic process models: Savage's account of progressive cathexis withdrawal, Leuner's model of inner stimulus overdrive and transphenomenal dynamic (tdyst) systems, and Grof's delineation of psychodynamic versus transpersonal realms (including COEX systems). These frameworks identify emotionally charged, condensed memory constellations as the likely content released during regression; their discharge and integration are proposed mechanisms of therapeutic change in psycholytic approaches. Fifth, the authors identify four central therapeutic principles of psycholytic healing: (1) regressive recapitulation and cathartic discharge of affect-laden biographical material, (2) gaining insight into how early events produced maladaptive defenses and patterns, (3) facilitation of transference processes that allow corrective relational experience, and (4) synthesis integrating disarmed affect into a more flexible character structure. The review argues that lasting change requires psycholytic penetration of character (habitual ego patterns) rather than transient ego regression alone. Finally, practical considerations and cautions are reported: certain clients (for example, those with fragile ego structures or active suicidal tendencies) are contraindicated for regressive approaches; set, setting and the therapeutic alliance strongly modulate outcomes; therapists require dense psychotherapeutic training because weakened defenses and altered self–other boundaries increase suggestibility and vulnerability. The authors also note that psychodynamic and cognitive-behavioural strategies are not mutually exclusive and may be complementary in integration and consolidation stages.

Buchborn et al. interpret their synthesis as arguing that psychedelics act in part by transiently weakening ego functions—loosening boundaries and defenses and enabling regression to earlier developmental modes—thereby opening access to emotionally charged memory constellations that have shaped a person's character. They locate the therapeutic opportunity in using this transient regression to achieve emotional discharge and insight, and then reintegrate that material into a strengthened and more flexible ego and character. Psycholytic therapy is presented as a coherent framework that aims for character maturation through repeated, lower-dose sessions embedded in psychodynamic psychotherapy. The authors situate their account relative to earlier research by connecting classical clinical observations from first-wave psychedelic work to contemporary neuroscientific models (e.g., DMN desynchronization, REBUS). They suggest that psychodynamic constructs—cathexis, regression, defenses, and character—can be meaningfully mapped onto network-level brain dynamics and predictive-processing accounts of perception and affect. This affords a cross-disciplinary bridge between psychodynamic theory and modern neurobiology of psychedelics. Key limitations acknowledged in the paper include the narrative, non-quantitative nature of the review and the heterogeneity of psychodynamic constructs across schools. The authors concede that many of the psychodynamic sources are clinical and phenomenological rather than statistically corroborated, and that their review is intended as a perspective rather than an exhaustive, systematic synthesis. They also note practical contraindications to psycholytic regression (for example, weak ego structures, active suicidality), and the risk that weakened boundaries can increase patient suggestibility and susceptibility to harmful social influences if clinical safeguards are inadequate. Regarding implications, the authors promote more rigorous operationalisation and measurement of ego functions, character types, defenses, and therapeutic process variables within psychedelic research. They recommend integrating psychometric instruments for ego and character assessment into clinical trials, and pursuing cross-disciplinary research linking psychodynamic process measures with neuroplasticity and network-synchronisation markers. Clinically, the review argues for careful attention to personality/character assessment, dose and session sequencing (to titrate degree of regression), and high standards of psychotherapeutic training and integrity for practitioners. Finally, they emphasise that psycholytic concepts can be compatible with other therapeutic modalities and that combining methods (for instance, psycholytic abreaction with cognitive-behavioural techniques for consolidation) may be beneficial.